Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Gobbles Up Micromet In $1.16 Billion BiTE

This article was originally published in The Pink Sheet Daily

Executive Summary

With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).

Advertisement

Related Content

Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody
Amgen Bispecific Antibody Blincyto Gets Green Light From Europe’s CHMP
Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached
Amgen Drives Into Immunotherapy With Early Blinatumomab BLA
Glenmark UpBEAT As Tech Yields First Oncology Lead
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing
Micromet Gets $14M Upfront From Amgen For BiTE Technology
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Micromet Reacquires Full North American Rights To Blinatumomab

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel